Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study

BackgroundSeveral disease-modifying drugs have shown promising effects on cognitive impairment in multiple sclerosis (MS). Alemtuzumab, a humanized monoclonal antibody, is effective in controlling disease activity, however, has not been evaluated for its effects on cognition in detail so far.Objecti...

Full description

Bibliographic Details
Main Authors: Ester Riepl, Steffen Pfeuffer, Tobias Ruck, Hubertus Lohmann, Heinz Wiendl, Sven G. Meuth, Andreas Johnen
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-01-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
immunomodulation
alemtuzumab
neuropsychology
cognition
neurocognitive disorders
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2017.00730/full

Internet

http://journal.frontiersin.org/article/10.3389/fneur.2017.00730/full

Similar Items